Good, bad and ugly: 3 UK shares with South Africa exposure

Three UK shares listed on the London Stock Exchange, each with exposure to South Africa amid the country’s chaotic politics and trying economic times.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With one third of the country unemployed, a former president sentenced to jail and anaemic GDP growth, South Africa is a complex investment destination. Covid-19 and lockdowns have injected calamity to decline. Still, this is the most advanced economy on the continent. South Africa boasts a world-class financial sector and natural resources. Here are three UK shares I’m watching with different sorts of exposure to precarious South Africa.

The good

Sylvania Platinum (LSE:SLP) is a producer and developer of platinum group metals (PGMs), platinum, palladium and rhodium. It has enviable low-cost operations in the element-rich Bushveld Igneous Complex and stellar recent performance. It got back to full production rapidly after the severe initial lockdown in the first half of 2020. Its third-quarter results to 31 March 2021 boasted net profit of $41.3m, more than double the prior quarter’s $20.3m. Fantastic cash reserves also enabled a once-off windfall dividend of 3.75p per share in April.

Moreover, Sylvania interests me as a bet on commodity prices and a hedge against inflation for investors in UK shares. The likes of UBS reckon platinum undersupply will continue while demand grows for the metal in catalytic converters and jewellery. With chatter about global inflation, commodities are a good defence against losing value to rising consumer prices.

The evergreen caveat with commodities is that prices can dip for extended periods, and even the best producers won’t win when that happens.

The bad

My “bad” stock is Old Mutual (LSE: OMU). Established in Cape Town in 1845, the insurance and financial services giant is a pillar of South African commerce. That makes it less of a bet on the business itself than on prospects for “South Africa Inc.”.

South Africa’s output growth has declined steadily from just over 3% in 2011 to zero before the pandemic. The economy shrank 7% in 2020. Covid-19 responses have depleted an already creaky fiscus. And politicians aren’t helping.

A planned constitutional amendment to allow land reform, likely in the shape of confiscation of land without compensation, is a frightening reminder of Zimbabwe’s violent farm takeovers and ensuing economic collapse. If this goes ahead, my outlook for South Africa and businesses that rise and fall with it turns dour.

I retain some hope that political haggling will scrap at least the “without compensation” part of the plan.  

The ugly

Mediclinic (LSE:MDC) runs private hospitals in South Africa. It serves a small elite who pay for private medical insurance. The harsh truth is that an unfortunate majority of people in this unequal society have no choice but to use the poorly resourced public system. However, that already regrettable status quo could change disastrously.

The proposed National Health Insurance (NHI) Bill would establish nationalised universal healthcare. A single, taxpayer-financed NHI Fund would buy healthcare services for the entire population from both public and private providers.

We don’t need the minutiae of the plan to calculate its potential for calamity. This redistributive system would spread too few medical resources among too many people, just as the wealthy tax base is fleeing. Doctors and nurses are departing, too.  

Owners of Mediclinic International’s UK shares can take solace in the company’s operations in Switzerland and the United Arab Emirates. But I won’t be buying while nationalisation is on the cards.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Macleod has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s the best-performing FTSE 100 stock of the last 10 years

Private equity firm 3i has outperformed the rest of the FTSE 100 over the last 10 years. And its big…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Here’s why Warren Buffett is selling shares (and why I’m not)

Warren Buffett cited tax considerations as his reason for selling shares in Apple. But this isn’t something most UK investors…

Read more »

Investing Articles

What on earth is going on with the AstraZeneca share price?

The AstraZeneca share price has fallen 30% from its peak in August. Dr James Fox explains what’s going on with…

Read more »

Investing Articles

2 high-yield FTSE 100 shares I’d consider buying for passive income…and one I’d avoid

Some FTSE 100 stocks have eye-popping dividend yields. But will the passive income actually be dished out? Paul Summers takes…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

These 2 former stock market darlings are trying my patience! Time to sell?

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks.…

Read more »

Investing Articles

Here’s how I’d use £3,000 to target a second income that grows each year

Our writer explains the approach he'd take to trying to build a second income that gets bigger over time, by…

Read more »

Elevated view over city of London skyline
Investing Articles

Is it time to buy this incredible FTSE dividend share?

Christopher Ruane examines one FTSE 100 share with a phenomenal dividend history. Does a steep share price fall this year…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

This FTSE 100 share has just crashed another 20%. Its P/E is now just 9.9 so should I buy?

Harvey Jones was tempted to buy this FTSE 100 share after it crashed in October. Now it's crashed again, it…

Read more »